X-Chem Expands Agreement with AstraZeneca
X-Chem Enters Expanded Global Drug Discovery Collaboration with AstraZeneca
--Establishes X-Chem as a Key Partner in AstraZeneca’s Drug Discovery Strategy--
WALTHAM, Mass.–Oct. 3, 2013-X-Chem, Inc.,a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics,today announced it has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company’s therapeutic areas and multiple target classes. The companies had entered into a previous collaboration in May of 2012. AstraZeneca recently elected to license three drug discovery programs resulting from that effort, directed at, respectively,an oncology protein-protein interaction (PPI) target, a respiratory/inflammation PPI target, and an antibacterial target. AstraZeneca has opted to extend the initial research collaboration from two to five years. X-Chem will conduct drug disco very on at least 10 therapeutic targets per yea rgoing forward.
Posted: October 2013